Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=725 A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
Immunodeficiency Virus Type 1, Human
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response)…
Phase 1 N=30 Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
COPD
Primary: Cmax — 53.75; 49.27; 166.79; 148.03 Pg/mL
Phase 4 N=361 Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
Healthy Volunteers
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis…
Phase 2 N=12 High-Dose Cyclophosphamide for Steroid Refractory GVHD
Graft Versus Host Disease
Primary: Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide — 4; 4; 2 Participants
Phase 2 N=349 Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135…
Phase 3 N=101 Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Crohn's Disease
Primary: Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 11.9 percentage of participants
Phase 4 N=150 Adductor Canal Block for Medial Compartment Knee Arthroplasty
Postoperative Analgesia · Medial Unicompartmental Knee Arthroplasty
Primary: Verbal Pain Scores at 6 Hours Post Nerve Blockade. — 1; 1.1; 1.6; 1.5 score on a scale
Phase 3 N=601 Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
Perennial Allergic Rhinitis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs). — 203; 41; 54 participants
Phase 3 N=177 An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Asthma · Elevated Blood Eosinophils · Oral Corticosteroid Dependence
Primary: Number of Participants With Reduction In Daily Oral Corticosteroid (OCS) Dose During Weeks 20-24 As Compared to the Optimized Dose At Baseline — 20; 18; 4; 8…
Phase 2 N=178 Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)
Chronic Hepatitis C
Primary: Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE) — 50.0; 0.0; 33.3; 33.3 Percentage of Participants
Phase 1 N=36 The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
Advanced Solid Tumours
Primary: Single Dose PK Parameter--Cmax — 6.875; 2.972 µg/mL
N/A N=198 A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Acute Ischemic Stroke From Large Vessel Occlusion
Primary: Number of Participants With Angiographic Revascularization of the Occluded Target Vessel — 82; 79 Participants
Phase 2 N=198 A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 14; 20; 21; 18 Participants
Phase 3 N=45 Bupivacaine With Epidural Volume Extension
Spinal Anesthesia · Epidural; Anesthesia
Primary: Time Until PACU Discharge in Minutes — 135; 50 minutes